Four MEK inhibitors are meanwhile FDA approved to treat melanoma, neurofibroma, NSCLC and thyroid cancer in stratified patients with BRAF or KRAS mutations. This evidence concerns the gene MAP2K7 and thyroid gland carcinoma.